These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25228368)

  • 1. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
    Jameson GS; Hamm JT; Weiss GJ; Alemany C; Anthony S; Basche M; Ramanathan RK; Borad MJ; Tibes R; Cohn A; Hinshaw I; Jotte R; Rosen LS; Hoch U; Eldon MA; Medve R; Schroeder K; White E; Von Hoff DD
    Clin Cancer Res; 2013 Jan; 19(1):268-78. PubMed ID: 23136196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
    Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
    Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etirinotecan pegol for the treatment of breast cancer.
    López-Miranda E; Cortés J
    Expert Opin Pharmacother; 2016; 17(5):727-34. PubMed ID: 26881332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
    J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
    Sy SK; Sweeney TD; Ji C; Hoch U; Eldon MA
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):57-67. PubMed ID: 27904955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
    Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
    Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
    [No Abstract]   [Full Text] [Related]  

  • 9. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
    Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
    Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etirinotecan pegol: an option for late-stage breast cancer?
    Nielsen DL; Brünner N
    Lancet Oncol; 2013 Nov; 14(12):1149-51. PubMed ID: 24095297
    [No Abstract]   [Full Text] [Related]  

  • 11. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.
    Alemany C
    Curr Oncol Rep; 2014 Feb; 16(2):367. PubMed ID: 24445499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
    Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Dieras V; Müller V; Tagliaferri M; Hannah AL; Cortés J
    Future Oncol; 2019 Jul; 15(19):2211-2225. PubMed ID: 31074641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
    Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
    Aggarwal C; Cohen RB; Yu E; Hwang WT; Bauml JM; Alley E; Evans TL; Langer CJ
    Clin Lung Cancer; 2018 Mar; 19(2):157-162. PubMed ID: 29129435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
    Lenz HJ; Philip P; Saunders M; Kolevska T; Mukherjee K; Samuel L; Bondarde S; Dobbs T; Tagliaferri M; Hoch U; Hannah AL; Berkowitz M
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1161-1169. PubMed ID: 29043412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
    Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
    Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
    Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
    Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Diéras V; Müller V; Du Y; Currie SL; Hoch U; Tagliaferri M; Hannah AL; Cortés J;
    JAMA Oncol; 2022 Jul; 8(7):1047-1052. PubMed ID: 35552364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.